Fig. 5: LOC promotes glioblastoma tumorigenesis.
a,b, In vitro LDA assay for tumorsphere formation for GBM131 (a) and GBM559 (b) cells (derived from patients with primary glioblastoma) with LOC knockdown with or without LOC overexpression. LDA clonogenic significance was measured by linear regression analysis. c, In vivo LDA for tumorsphere formation in GBM131 cells with LOC knockdown with or without LOC overexpression. Mice were implanted with different numbers of cancer cells (1 × 104, 5 × 104 or 2.5 × 105). The ratios indicate the tumor engraftment rate of GBM131 cells with LOC knockdown with or without LOC overexpression. d, Cells derived from patients with primary glioblastoma were infected with control shRNA or one of two independent shRNA targeting LOC and treated with DMSO or TMZ. Cell viability was measured using an ATPlite assay and data were normalized to the DMSO-treated control shRNA-transduced cells. e, Patient-derived glioblastoma cells were infected with control shRNA, LOC shRNA1 or LOC shRNA2 vectors and then injected into mice (n = 8), which were analysed for survival. f, Representative haematoxylin and eosin-stained sections of the mouse brains from e. The red lines delineate tumours. g, Immunofluorescence images of orthotopic model-derived tumour samples stained with nestin. h, Proportion of cells in g that were nestin+; three fields per sample. d,h, The data represent the mean ± s.e.m. of n = 3 biologically independent samples. d,e,h, P values were determined using a two-tailed Student’s t-test (d,h) or two-sided log-rank test (e). Source numerical data are provided.
